CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:mRNA-based CAR T-cells manufactured by miniaturized two-step electroporation produce selective cytotoxicity toward target cancer cells.
mRNA-based CAR T-cells manufactured by miniaturized two-step electroporation produce selective cytotoxicity toward target cancer cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
由于无病毒载体的嵌合抗原受体(CAR)T细胞能够在不产生不良副作用的情况下杀死癌细胞,人们对其兴趣日益浓厚。生产无病毒载体CAR-T 细胞的一个潜在途径是利用mRNA电穿孔。mRNA电穿孔CAR-T 细胞的主要问题之一是细胞毒性寿命较短,仅几天,这对于治疗来说不够或不够理想。为了更好地理解这一问题并开发潜在的解决方案,本研究聚焦于检测电穿孔mRNA向CAR分子的翻译、CAR分子的时间依赖性降解以及CAR-T 细胞对癌细胞产生的细胞毒性。研究发现,CAR分子的初始表达决定了细胞毒性。初始CAR表达可以通过实验参数控制,例如电穿孔时间和电穿孔缓冲液中的mRNA浓度。实验采用了一种新型两步电穿孔法,该方法允许对T细胞进行可控且均匀的转染。这些技术进步及后续发现可能为生产具有更长细胞毒性寿命的CAR-T 细胞提供一条可行路径。
There is a growing interest for viral vector-free chimeric antigen receptor (CAR) T-cells due to its ability to kill cancer cells without adverse side effects. A potential avenue for manufacturing viral-vector free CAR T-cells is to utilize mRNA electroporation. One of the major concerns with mRNA electroporated CAR T-cells is the shorter cytotoxic lifespan of a few days, which is insufficient or not ideal for therapy. To better understand this issue and develop a potential solution, this study focused on examining the translation of electroporated mRNA to CAR molecules, time dependent degradation of CAR molecules and cytotoxicity produced by CAR T-cells on cancer cells.
It was found that the initial expression of CAR molecules dictates the cytotoxicity. Initial CAR expression could be controlled by the experimental parameters such as electroporation time and mRNA concentration in the electroporation buffer. Experiments were carried out using a novel two-step electroporation that allows for controlled and uniform transfection of T-cells. These technical advancements and subsequent findings could provide a viable path for producing CAR T-cells with longer cytotoxic lifespans.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。